Related by context. All words. (Click for frequent words.) 77 Phase 2b Clinical Trial 75 Clinical Trial Results 75 Phase III Clinical Trial 74 Meets Primary Endpoint 74 Presents Preclinical 73 Phase IIb Trial 73 Pivotal Study 73 Presents Positive 73 Phase IIb Clinical Trial 73 Tezampanel 73 Completes Enrollment 73 Drug Candidate 72 Initiate Phase 72 Presents Preclinical Data 72 Initiates Phase III 72 Phase 2a Trial 72 Preclinical Data 72 Initiates Clinical 72 Completes Patient Enrollment 72 Pivotal Phase III 71 Phase III Trial 71 Hsp# Inhibitor 71 Phase 2b Study 71 Phase III Trials 71 Announces Poster Presentations 71 Phase 2a Clinical Trial 70 Initiates Phase II 70 Demonstrates Significant 70 JAK Inhibitor 70 Patient Enrollment 70 Receives Orphan Drug Designation 70 Achieves Primary Endpoint 70 Pivotal Phase 70 Present Preclinical Data 70 Initiates Clinical Trial 70 Randomized Phase 70 Investigational Compound 69 Investigational Treatment 69 Pivotal Trial 69 FOLOTYN ® 69 Phase 2b Trial 69 Previously Treated 69 II Clinical Trial 69 MEK Inhibitor 69 Demonstrates Positive 69 First Patient Dosed 69 Late Breaker 69 Personalized Immunotherapy 69 Combination REOLYSIN R 69 Begins Dosing 68 Oral Fingolimod 68 Antitumor Activity 68 Protease Inhibitor 68 Novel Antibiotic 68 Novel Oral 68 Immunotherapeutic 68 Pafuramidine 68 Patients Treated With 68 HDAC Inhibitor 68 Receives Orphan Drug 68 Elagolix 68 Monotherapy 68 Multiple Ascending Dose 68 Vicriviroc 68 Successfully Completes Phase 68 Pooled Analysis 68 Phase III Clinical Trials 68 Trial Evaluating 68 Initiates Clinical Trials 68 Ranolazine 68 Metastatic Melanoma 68 Initiates Enrollment 68 Receives Milestone Payment 68 Denufosol 68 Files IND 68 Orally Active 68 Investigational Drug 67 ALN HPN 67 Telbivudine 67 Adjuvant Treatment 67 Initiates Phase 2b 67 Phase III Pivotal Trial 67 non nucleoside inhibitor 67 Reveals Positive 67 Kinase Inhibitor 67 Lung Cancer Trial 67 Prolongs Survival 67 Single Dose 67 Romidepsin 67 Hormone Refractory Prostate Cancer 67 Submits NDA 67 Initiate Clinical Trial 67 Reports Preclinical Data 67 Receptor Agonist 67 mGluR5 negative 67 Sapacitabine 67 Phase IIa Clinical Trial 67 Preclinical Efficacy 67 Trandolapril 67 Pivotal Trials 67 HCV Protease Inhibitor 67 evaluating tivozanib 67 Mycophenolate Mofetil 67 Novel Mechanism 67 Acute Ischemic Stroke 67 Double Blind Placebo 67 Preclinical Study 66 generation purine nucleoside 66 Demonstrated Significant 66 Spectrum Pharmaceuticals Announces 66 Glatiramer Acetate 66 Controlled Trial 66 Aliskiren 66 Therapeutic Potential 66 Pulmonary Arterial Hypertension 66 IL# PE#QQR 66 Well Tolerated 66 Clinical Trial Evaluating 66 Preclinical Models 66 Recombinant Human 66 Archexin 66 First Patient Enrolled 66 Combination Therapy 66 Albuferon TM 66 Initiates Phase 66 Advanced Melanoma 66 Oral Insulin 66 Vaccine Adjuvant 66 Brentuximab Vedotin SGN 66 Lupus Drug 66 Dose Escalation 66 Chronic Hepatitis C 66 JAK2 Inhibitor 66 Aflibercept 66 Interferon Beta 66 Patients Treated 66 Study Evaluating 66 Oral Calcitonin 66 Granted Orphan Drug 66 Topline Results 66 Randomized Clinical Trial 66 ASCO GI 66 Study Showed 66 Severe Sepsis 66 Phase 1a clinical 66 Tiotropium 66 oral prodrug 66 nucleoside analog 66 Ozarelix 66 Hepatocellular Carcinoma 66 Dose Ranging Study 65 TLK# 65 Long Term Efficacy 65 Naproxcinod 65 NDA Submission 65 Relapsed Multiple Myeloma 65 Novel Inhibitor 65 ACOMPLIA R 65 Combination Treatment 65 Initiate Phase III 65 Voreloxin 65 ALN PCS 65 Prospective Randomized 65 Phase Ib Clinical Trial 65 Safinamide 65 Randomized Double blind 65 Microplasmin 65 MKC# MT 65 Advanced Renal Cell 65 Trodusquemine MSI 65 Elesclomol 65 AASLD Meeting 65 liposomal formulation 65 phase IIb trial 65 Emerging Therapies 65 Targeted Therapies 65 Investigational Oral 65 Cites Positive 65 ORAL Sync 65 Shows Promising 65 Orally administered 65 TKB# 65 Commences Phase 65 Demonstrates Efficacy 65 Tyrosine Kinase Inhibitor 65 Files Investigational 65 Phase #/#a 65 Statistically Significant 65 Complicated Skin 65 Parathyroid Hormone 65 Pirfenidone 65 Golimumab 65 Demonstrates Potential 65 Cholesterol Lowering Drug 65 Is Well Tolerated 65 Randomized Double Blind Placebo 65 Oral Formulation 65 RNAi Therapeutic 65 Receives Approvable Letter 65 Placebo Controlled Trial 65 IND Application 65 Survival Benefit 65 Phase IIIb clinical 65 orally administered inhibitor 65 Phase IIa Trial 65 Fondaparinux 65 Tigecycline 65 Anticancer Agent 65 allosteric modulator NAM 65 Renal Cell Carcinoma 65 Diabetic Neuropathy 65 Improves Survival 65 Newly Diagnosed Multiple Myeloma 65 Therapeutic Vaccine 65 Collaborators Present 65 including eniluracil ADH 65 Therapeutic Competitors Companies 65 DDP# 65 pan HDAC inhibitor 65 Panzem R 64 Aurora Kinase 64 CYT# potent vascular disrupting 64 pralatrexate injection folate analogue 64 Drug Fails 64 Methylnaltrexone 64 Pivotal Clinical Trial 64 novel VDA molecule 64 PNP inhibitor 64 FDA Accepts 64 Oral Insulin Capsule 64 Anti Tumor 64 Demonstrates Potent 64 Phase Ib study 64 inhalation powder 64 virus HCV protease inhibitor 64 Controlled Study 64 transthyretin TTR mediated amyloidosis 64 Phase 1b clinical trials 64 mGluR5 NAM 64 Gastrointestinal Stromal Tumors 64 Phase #b/#a clinical 64 Shows Efficacy 64 azilsartan medoxomil 64 PEGylated Fab fragment 64 FDA APPROVES 64 fosbretabulin 64 vidofludimus 64 Transdermal Patch 64 Milestone Payment 64 Adjunctive Therapy 64 SAR# [004] 64 Efficacy Trial 64 Dapagliflozin 64 Zenvia Phase III 64 Chronic Myeloid Leukemia 64 Cutaneous T 64 Confirmatory Phase 64 Inflammatory Arthritis 64 AAG geldanamycin analog 64 Interferon Gamma 64 Medoxomil 64 Eniluracil 64 Rotavirus Vaccine 64 Hematological Malignancies 64 Randomized Phase II 64 AFREZZA TM 64 sodium glucose cotransporter 64 Submits IND 64 investigational oral inhibitor 64 Systemic Delivery 64 Vascular Disrupting Agent 64 Metabolic Efficiency 64 IMiDs ® 64 Maribavir 64 Earns Milestone Payment 64 Treating Chronic 64 Allergic Rhinitis 64 Glufosfamide 64 IND Filing 64 Antibody Drug Conjugate 64 CCX# B 64 Phase 1b Clinical Trial 64 Muraglitazar 64 selective androgen receptor modulator 64 Improves Outcomes 64 2 methoxyestradiol 64 Solazed TM 64 registrational trial 64 seliciclib CYC# 64 VIVUS Announces 64 PRN FDA Approves 64 Lubiprostone 64 Low Dose 64 MBRX 64 Dendritic Cells 64 KRN# 64 generation antisense inhibitor 64 Rigel R# 64 INSPIRE Trial Phase III 64 Hypercholesterolemia 64 Improved Survival 64 CEQ# 64 albiglutide 64 evaluating mipomersen 64 Elderly Patients 64 hyperphenylalaninemia HPA due 64 Lupus Nephritis 64 evaluating picoplatin 64 Benign Prostatic Hyperplasia 64 severe hypercholesterolemia 63 SYN# 63 Tesetaxel 63 beta 1a 63 Tolerability 63 Ridaforolimus 63 Oral Presentations 63 Shows Statistically Significant 63 polycythemia vera essential thrombocythemia 63 investigational humanized monoclonal antibody 63 Relapsing Multiple Sclerosis 63 Enoxaparin 63 Prodrug 63 Bosutinib 63 CRMD# 63 omacetaxine mepesuccinate 63 Patients Receiving 63 Poster Presentations 63 Pharmacokinetics PK 63 Treated Patients 63 Significantly Improves 63 Dose Ranging 63 Phase #b/#a trial 63 Tasimelteon 63 ceftazidime 63 RNAi Therapeutics 63 FDA Okays 63 Cetrorelix 63 Vildagliptin 63 receptor tyrosine kinase inhibitor 63 ALN TTR 63 Enzyme Replacement Therapy 63 Receptor Antagonist 63 Receives Fast Track 63 Chronic Heart Failure 63 Ambrisentan 63 Fast Track Status 63 intranasal formulation 63 By JENNIFER LEARN 63 Adjuvant Therapy 63 TO AVOID PREGNANCY WHILE 63 TMC# [002] 63 phase IIa clinical 63 PSN# [002] 63 catheter occlusion 63 Potent Inhibitor 63 AVAPRO 63 Phase #/#a trial 63 SPRYCEL ® 63 riociguat 63 Boceprevir 63 Sangamo BioSciences Announces 63 cMET 63 INCB# [001] 63 highly selective inhibitor 63 phase IIb clinical 63 Metastatic Colorectal Cancer 63 Cethromycin 63 Pertuzumab 63 Biomarker Study 63 Relapsed Refractory 63 Gout Drug 63 Insulin Resistance 63 Parkinson disease levodopa induced 63 Completes Dosing 63 Humanized Anti 63 GW# [003] 63 HFA MDI 63 peripherally acting 63 DU #b 63 LymphoStat B TM 63 JAK2 inhibitor 63 molecular imaging radiopharmaceutical 63 CYP#A# CYP#D# 63 Antitumor 63 Chronic Hepatitis B 63 Pimavanserin 63 Licenses Novel 63 Significantly Reduces 63 MKC# 63 LibiGel ® 63 GALNS 63 generation PNP inhibitor 63 interferon gamma 1b 63 Novel Therapeutic 63 Telaprevir VX 63 metaglidasen 63 TPI ASM8 63 Angiogenic 63 lintuzumab SGN 63 Squalamine 63 Rheumatoid Arthritis Patients 63 Xcytrin R 63 HoFH 63 Oral Mucositis 63 Randomized Double Blind 63 Inhalation Solution 63 docetaxel Taxotere ® 63 Disease Progression 63 Serious Infections 63 initiated Phase Ib 63 Fidaxomicin 63 Subgroup Analysis 63 oral renin inhibitor 63 REG1 Anticoagulation System 63 Anti Tumor Activity 63 Treatment Naïve 63 Kamada AAT 63 Potent Antiviral Activity 63 Replacement Therapy 63 Zoledronic Acid 63 LENALIDOMIDE 63 induced macular edema 63 R lenalidomide 63 Completes Patient Enrolment 63 novel histone deacetylase 63 Initiated Phase 63 Daclizumab 63 Antiangiogenic 63 nitric oxide donating prostaglandin 63 Bazedoxifene 63 Randomized Study 63 Protease Inhibitors 63 Patent Covering 62 OMP #M# 62 Irbesartan 62 Phase IIb clinical trials 62 TELINTRA R 62 oral picoplatin 62 PRT# 62 PEGylated anti 62 novel orally inhaled 62 VIVITROL ® 62 STELARA TM 62 Hepatitis C Virus 62 rasagiline tablets 62 hypereosinophilic syndrome 62 ASH Annual Meeting 62 Systemic Sclerosis 62 Solid Tumors 62 FDA Approvals 62 Blinatumomab 62 Infected Patients 62 Phase IIa trials 62 huC# DM4 62 ThermoDox R 62 eosinophilic asthma 62 ISTODAX ® 62 MKC# MKC# PP 62 oral salmon calcitonin 62 Presents Positive Preclinical 62 Tumor Response 62 Drug Shows Promise 62 Tanespimycin 62 Anticancer Drug 62 Platelet Inhibition 62 Pharmacokinetic Study 62 Multiple Myeloma Patients 62 Elvitegravir 62 Study Demonstrates 62 Submits Response 62 Angiotensin Converting Enzyme 62 Efficacious 62 Peginterferon alfa 2b 62 PDE4 inhibitor 62 Overactive Bladder 62 Atripla combines 62 Factor Receptor 62 Nicotine Vaccine 62 Heart Transplant Recipients 62 Anticancer Compound 62 Diabetic Nephropathy 62 Dasatinib 62 Myocardial Infarction Study 62 PEG SN# 62 AACR symposium 62 relapsed MM 62 phase IIa 62 Phase 2a clinical trials 62 Selective Cardiac Myosin Activator 62 IIa Clinical Trial 62 dependent kinase inhibitor 62 Cerebril TM 62 Melphalan 62 Patients Suffering 62 ongoing Phase 1b 62 Lung Cancer Drug 62 MEND CABG 62 Ecallantide 62 multicenter Phase III 62 CD# CEA 62 phase III isavuconazole 62 Pharmacokinetic 62 Left Ventricular Dysfunction 62 Disease Modifying 62 Collaborators Publish 62 Irinotecan 62 Hypertensive Patients 62 Double Blind Randomized 62 phase IIb study 62 Therapeutic Targets 62 CCX# 62 Bicifadine 62 Patient Enrolment 62 lucinactant 62 assessing T DM1 62 GLYX 62 lexidronam injection 62 R#/MEM # 62 Migraine Drug 62 palifosfamide Zymafos TM 62 Inhalation Aerosol 62 oral nucleoside analogue 62 Vitro Activity 62 ritonavir boosted 62 orally inhaled migraine 62 compound INCB# 62 Phase III Pivotal 62 Nilotinib 62 indinavir Crixivan 62 Pegloticase 62 Therapeutic Antibody 62 Resistant Hypertension 62 Rheumatoid Arthritis Drug 62 GVAX ® 62 INCB# [003] 62 methylnaltrexone bromide 62 Phase 2a trial 62 Small Molecule 62 Hedgehog Pathway Inhibitor 62 brivaracetam 62 Peginterferon 62 thetreatment 62 EGFR HER2 62 Spiegelmer ® 62 Colorectal Cancer Patients 62 vascular disrupting agent 62 Announces Tentative Approval 62 TRANSFORMS 62 Clevudine 62 Omacetaxine 62 TRO# 62 essential thrombocythemia ET 62 Brain Metastases 62 Genasense ® oblimersen 62 toenail onychomycosis 62 elotuzumab 62 Hepatitis C Virus HCV 62 FOR FURTHER INFORMATION ABOUT 62 Submits Biologics License Application 62 Castration Resistant Prostate Cancer 62 BAL# [002] 62 CIMZIA TM certolizumab pegol 62 pan histone deacetylase 62 apoptosis inducer 62 Sirolimus Eluting Stent 62 Acute Heart Failure 62 oropharyngeal candidiasis OPC 62 miconazole Lauriad ® 62 Lanthanum Carbonate 62 Improve Survival 62 alvespimycin 62 BRIM2 62 Receives Positive Opinion 62 refractory chronic lymphocytic 62 Onyx Pharmaceuticals Announces 62 DIFICID ™ 62 Epratuzumab 62 evaluating satraplatin 62 HCV polymerase inhibitors 62 Phase #b/#a 62 radezolid 62 selective modulator 62 Announces Presentation 62 Monoclonal Antibody 62 DermaVir Patch 62 #th Annual Interscience 62 Bortezomib 62 ATL# [001] 62 TRX1 62 trodusquemine 62 Treatment Experienced 62 GATTEX TM 62 FOLFOX6 chemotherapy regimen 62 Phase 1b trial 62 Empatic TM 62 forodesine 62 torezolid phosphate 62 dihydrochloride Tablets 62 Myeloma Patients 62 PHX# 62 Naive Patients 62 Doripenem 62 histone deacetylase HDAC inhibitor 61 monoclonal antibody conjugated 61 Antiviral Activity 61 Commence Phase 61 Novel Compound 61 Febuxostat 61 Postmenopausal Women 61 Clinical Efficacy 61 CR# vcMMAE 61 Central Retinal Vein 61 small molecule thrombopoietin 61 RNAi therapeutic targeting PCSK9 61 Avanafil 61 protein tyrosine phosphatase 1B 61 IN PATIENTS WITH 61 Ixabepilone 61 Proteasome 61 Stent Restenosis 61 Exelixis XL# 61 insulin glulisine 61 mGluR2 positive 61 hoFH 61 Gets FDA Clearance 61 Initiates Dosing 61 dimebon latrepirdine 61 delafloxacin 61 Plaque Psoriasis 61 Demonstrates Sustained 61 Previously Untreated 61 mitogen activated ERK kinase 61 Myoblast 61 sunitinib Sutent 61 Azacitidine 61 volociximab 61 Adefovir 61 Valopicitabine 61 Versus Placebo 61 Pharmacodynamics 61 Lymphocytic 61 dyskinesia PD LID 61 RGB # 61 TNF Tumor Necrosis Factor 61 BRIM3 61 Randomised Trial 61 Anturol TM 61 CCR5 mAb 61 Inhaled Corticosteroids 61 PEGylated interferon beta 1a 61 Cloretazine ® 61 SUTENT ® 61 Acute Attacks 61 MOVIPREP R 61 phase IIb 61 miconazole MBT 61 Percutaneous Tibial Nerve Stimulation 61 Confirms Efficacy 61 Opterone R 61 Fixed Dose Combination 61 Toremifene 61 MEK inhibitor 61 sapropterin dihydrochloride 61 BiTE R 61 Prophylactic Treatment 61 selective S#P# receptor agonist 61 Panzem ® 61 Secondary Hyperparathyroidism 61 Androxal TM 61 Metastatic Prostate Cancer 61 Efficacy Results 61 Unfractionated Heparin 61 Patient Outcomes 61 Zoraxel 61 Subtypes 61 Clinical Outcome 61 ZYBRESTAT TM 61 Epanova 61 plus Copegus R 61 Neuroprotective Effects 61 Polymerase Inhibitor 61 Sirolimus Eluting 61 EVIZON TM 61 Ciclesonide 61 ® pioglitazone HCl 61 CML CP 61 CG# [003] 61 Demonstrate Significant 61 acyclovir Lauriad R 61 Inflammatory Markers 61 GOUT 61 Evoltra ® 61 Varespladib 61 Vascular Inflammation 61 Belimumab 61 diabetic neuropathic pain 61 topically applied SEPA 61 SNT MC# 61 Xanafide 61 XL# anticancer compounds 61 multicenter placebo controlled 61 Rosuvastatin 61 BEMA Granisetron 61 Metastatic Renal Cell Carcinoma 61 Placebo Controlled 61 Develop Novel 61 ADP receptor antagonist 61 FDA Clears 61 SPP# Rasilez 61 Nonalcoholic Steatohepatitis 61 Phase III ADT 61 mertansine 61 dasatinib Sprycel ® 61 Phase IIIb 61 Immunogenicity 61 Cancer Vaccines 61 APEX PD 61 RELOVAIR ™ 61 anticancer compound 61 PRTX 61 Iron Overload 61 myelodysplastic myeloproliferative diseases 61 PD LID 61 Intravenous Formulation 61 Decitabine 61 eprotirome 61 Phase 2a 61 Osteoporosis Treatment 61 PANVAC VF 61 velafermin 61 Prodarsan R 61 THERAPEUTICS 61 Enrolls First 61 PKC# 61 Lisofylline LSF 61 Shows Promise Against 61 Zenvia ™ 61 Mipomersen 61 vapreotide acetate 61 Kidney Transplant Patients 61 rabeprazole 61 Annamycin 61 GVAX R 61 SinuNase TM 61 CYT# QbG# 61 dextromethorphan quinidine 61 Autologous Stem Cell Transplantation 61 Intravitreal 61 Hepatotoxicity 61 Atopic Dermatitis 61 Traficet EN 61 ZEVALIN ® 61 Plicera 61 Soft Tissue Sarcoma 61 corticotropin injection 61 orally bioavailable 61 Phenoptin 61 midstage clinical 61 Chemokine Receptor 61 IMA# 61 polymerase inhibitor 61 EGS# 61 thalidomide Thalomid 61 AKT inhibitor 61 PEG IFN 61 AACR San Antonio 61 Androgen Independent 61 DIRECT Trial 61 Genasense oblimersen sodium Injection 61 Dupuytren Contracture 61 Anticancer Activity 61 Pegylated Interferon 61 Nucleoside 61 brand ciclesonide HFA 61 Immunomedics Announces 61 candidate XP# 61 Phase Ib II 61 Rebif interferon beta 1a 61 ularitide 61 itraconazole Sporanox 61 Lodotra TM 61 Gastric Cancer 61 metastatic castration resistant 61 Sprycel dasatinib 61 Capecitabine 61 inhaled formulation 61 Meta Analysis 61 Cardiotoxicity 61 FDA Approvable Letter 61 Knee Osteoarthritis 61 JAK1 61 Synta Announces 61 Ofatumumab 61 hyaluronidase enzyme 61 glucokinase activator 61 Zorbtive TM 61 RhuDex ® 61 Pegylated Liposomal Doxorubicin 61 #nd EORTC NCI 61 PHASE III 61 Prostate Cancer Patients 61 Zybrestat 61 Myelodysplastic Syndrome MDS 61 Dose Finding 60 Diabetic Macular Edema DME 60 Primary Endpoint 60 Mg Usa 60 Tesamorelin 60 Effectively Treats 60 Testosterone MDTS ® 60 diarrhea predominant irritable 60 retinal vein occlusion induced 60 ORENCIA ® 60 aurora kinase 60 Transdermal Delivery 60 Universal Flu Vaccine 60 BARACLUDE ® 60 HCV polymerase 60 JZP 60 cancer neuroendocrine tumor 60 Extended Release 60 humanized monoclonal 60 TBC# 60 5 FU leucovorin 60 Deforolimus 60 Amrubicin 60 Kuvan TM sapropterin 60 Multicenter Randomized 60 Panzem R NCD 60 Prostate Cancer Vaccine 60 LEVADEX ™ 60 BioDelivery Sciences Announces 60 Receives Complete Response 60 Eluting Stent 60 Epidermal Growth Factor Receptor 60 NS#/#A protease 60 Severe Asthma 60 Clinical Evaluation 60 corticosteroid dexamethasone 60 metastatic malignant 60 Receives SFDA Approval 60 Cancer Patients Treated 60 Vitrasert R 60 Carfilzomib 60 Attenuates 60 novel oral anticoagulant 60 Bavituximab 60 phase Ib 60 Optimer Pharma 60 developing Zerenex ferric 60 PROSTASCINT R 60 Epilepsy Drug 60 Saquinavir 60 #/#mg 60 HuMax EGFr 60 SABCS 60 Phase Ib clinical 60 Statin Therapy 60 novel emulsion formulation 60 HER2 Positive 60 Seliciclib 60 developing Bicifadine serotonin 60 Xeloda ® 60 Diabetic Macular Edema 60 baminercept 60 Vascugel 60 E1 INT TM 60 Vaccine Protects Against 60 Kuvan R 60 Pramlintide 60 ExTRACT TIMI 60 Eltrombopag 60 Valsartan 60 hypoxia activated prodrug 60 evaluating bafetinib 60 RhuDex 60 Schizophrenia Treatment 60 xanthine oxidase inhibitor 60 Phase IIb trials 60 Alvesco R 60 Receptor Antagonists 60 generation URAT1 inhibitor 60 VitiGam TM 60 Fixed Dose 60 targeted radiotherapeutic 60 AACR NCI EORTC 60 inhibitor RG# 60 acute peripheral arterial 60 clinical pharmacology studies 60 HCV SPRINT 60 atazanavir sulfate 60 Serdolect ® 60 familial amyloidotic polyneuropathy FAP 60 3 registrational trial 60 Bosentan 60 KRYSTEXXA TM pegloticase 60 Newly Diagnosed 60 Interferon Alpha 60 BARACLUDE R 60 COX Inhibiting Nitric Oxide 60 tanespimycin 60 Cleviprex TM clevidipine 60 5 HT3 antagonist 60 Annual Interscience Conference 60 ABLYNX 60 pharmacokinetic PK study 60 CCR9 antagonist 60 Fluconazole 60 VEGFR2 inhibitor 60 Announces Positive 60 Pemphigus Vulgaris 60 AEG# 60 antiplatelet agent 60 Antiviral Therapy 60 MAGE A3 ASCI 60 Announces Publication 60 Clinical Trial Data 60 Solulin 60 pharmacokinetic PK 60 Diabetic Patients 60 Darusentan 60 6R BH4 60 R roscovitine 60 Formoterol 60 ALVESCO R 60 Anthracycline 60 CTAP# Capsules 60 oral proteasome inhibitor 60 proteasome inhibitor 60 ACE Inhibitors 60 Randomized Clinical Trials 60 Patients Enrolled 60 Significantly Improved 60 p# inhibitor 60 Bayer Onyx 60 BioSante Pharmaceuticals Announces 60 Iluvien ® 60 Treatment Naive Patients 60 Onalta ™ 60 Prognostic Significance 60 blinded randomized placebo controlled 60 tenofovir emtricitabine 60 dihydrochloride 60 Premarket Approval Application 60 non peptidic protease 60 Bivalirudin 60 Trastuzumab DM1 60 Expanded Indication 60 GATTEX ™ 60 Fosphenytoin 60 CRLX# 60 Molecular Diagnostic Test 60 Marqibo TM 60 Milestone Payments 60 Malignant Melanoma 60 Successfully Treated 60 MCSP respectively 60 Saforis 60 Reminyl galantamine 60 trastuzumab Herceptin R 60 OMNARIS Nasal Spray 60 selective estrogen receptor modulator 60 Release Capsules 60 Society CTOS 60 Phase 2b monotherapy 60 Generic Version 60 ARRY # 60 histone deacetylase inhibitor 60 Pegylated 60 lorvotuzumab mertansine 60 BENLYSTA ® 60 Liposomal 60 RANK Ligand inhibitor 60 TM Drug Eluting 60 Tolvaptan 60 Telithromycin 60 Initiate Phase II 60 Placebo Controlled Study 60 LymphoStat B belimumab 60 Selective Cardiac Myosin 60 Sustained Reduction 60 systemic RNAi therapeutic 60 Reports Positive 60 Sitagliptin 60 PDUFA Date 60 ALN VSP Phase 60 Refractory Angina 60 Pemetrexed 60 Phase IIB 60 RELOVAIR TM 60 Actimmune ® 60 budesonide foam 60 AZT zidovudine Retrovir 60 BrachySil TM 60 Acute Myocardial Infarction 60 Ophena TM 60 sublingual tablet 60 candidates Azedra 60 Arthritis Drug